Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Celgene Corp. (NASDAQ: CELG).

Full DD Report for CELG

You must become a subscriber to view this report.


Recent News from (NASDAQ: CELG)

Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions
Presentations highlight the value of innovative research in key disease areas including multiple myeloma, lymphoma, acute myeloid leukemia and squamous non-small cell lung cancer, as well as novel CAR T technology Celgene Corporation (NASDAQ: CELG) today announced that data from more ...
Source: Business Wire
Date: May, 16 2018 17:30
2018 Bank of America Merrill Lynch Conference Call
The following slide deck was published by Celgene Corporation in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 16 2018 17:17
Celgene's (CELG) Management Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)
Celgene Corporation (CELG) Bank of America Merrill Lynch Healthcare Conference Call May 16, 2018 1:00 P.M. ET Executives Peter Kellogg - Chief Financial Officer Analysts Ying Huang - Bank of America Merrill Lynch Presentation Ying Huang I guess we should get started. ...
Source: SeekingAlpha
Date: May, 16 2018 17:11
INVESTOR ALERT: The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)
NEW YORK, NY / ACCESSWIRE / May 16, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Celgene Corporation (NASDAQ: CELG) who purchased shares between January 12, 2015 and February 27, 2018. The action, which was filed in the United ...
Source: ACCESSWIRE IA
Date: May, 16 2018 15:30
Generic Revlimid Could Sink Celgene
Blow ups in its Celgene's ( CELG ) R&D pipeline have caused bulls to question the company's future growth. Generic drug makers could now pose challenges to Revlimid, the company's blockbuster cancer treatment. Celgene is currently embroiled in a tete-a-tete with Mylan ( MYL ) over its ref...
Source: SeekingAlpha
Date: May, 16 2018 13:11
Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead Plaintiff Deadline
SAN FRANCISCO , May 16, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in Celgene Corporation ( NASDAQ: CELG ) of the May 29, 2018 securities class action Lead Plaintiff deadline .  If you purchased or otherwise acquired Celgene securities between Ja...
Source: PR Newswire
Date: May, 16 2018 10:07
Today's Research Reports on Trending Tickers: Celgene and Valeant Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 16, 2018 / U.S. markets slumped Tuesday, with the Dow Jones breaking an 8-day win streak, as interest rates surged to new highs. The Dow Jones Industrial Average declined 0.78 percent to close at 24,706.41, while the S&P 500 Index fell 0.68 percent to clo...
Source: ACCESSWIRE IA
Date: May, 16 2018 08:20
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 - CELG
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Celgene Corporation ("Celgene") (NASDAQ: CELG) between January 12, 2016 and February 27, 2018 . ...
Source: ACCESSWIRE IA
Date: May, 15 2018 13:55
Nohla Therapeutics Announces Closing of $45 Million Series B Financing
SEATTLE, May 15, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases, today announced the closing of a $45 million Series B financing. In this round, Fidelity Manage...
Source: GlobeNewswire
Date: May, 15 2018 13:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1781.0879.9881.2279.1510,246,824
2017-12-29104.27104.36105.36104.154,500,810
2017-12-28104.74104.75105.5747104.083,927,803
2017-12-27106.57104.46107.209104.105,967,386
2017-12-26105.96106.97107.33105.682,688,150

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-21314,414993,11331.6594Cover
2018-08-20635,7701,377,21846.1634Short
2018-08-17330,6651,001,24433.0254Cover
2018-08-16196,889746,84626.3627Cover
2018-08-15356,0511,658,24121.4716Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CELG.


About Celgene Corp. (NASDAQ: CELG)

Logo for Celgene Corp. (NASDAQ: CELG)

Not available

 

Contact Information

 

 

Current Management

  • Robert J. Hugin / CFO

Current Share Structure

  • Market Cap: $59,421,326,724 - 05/15/2018
  • Issue and Outstanding: 724,827,113 - 04/23/2018

 


Recent Filings from (NASDAQ: CELG)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 04 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 06 2018
Amendment to a previously filed SC TO-T
Filing Type: SC TO-T/AFiling Source: edgar
Filing Date: March, 05 2018

 

 


Daily Technical Chart for (NASDAQ: CELG)

Daily Technical Chart for (NASDAQ: CELG)


Stay tuned for daily updates and more on (NASDAQ: CELG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CELG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CELG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CELG and does not buy, sell, or trade any shares of CELG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/